Table 2.
Cancer risk following lymphoid malignancies among HIV-infected people.
| Cancers | Number of cancers (N) | Number with first primary lymphoid malignancies [N (row %)] | aHR (95% CI) Model 1a | aHR (95% CI) Model 2a |
|---|---|---|---|---|
| Any first nonlymphoid cancer | 18 944 | 226 (1.2) | 2.7 (2.3–3.2) | 1.7 (1.5–2.0) |
| Oral cavity | 511 | 7 (1.4) | 2.6 (1.2–5.5) | 1.9 (0.9–4.0) |
| Colon | 601 | 7 (1.2) | 2.4 (1.1 −5.0) | 2.0 (1.0–4.3) |
| Rectum | 549 | 10 (1.8) | 3.6 (1.9–6.7) | 2.7 (1.5–5.1) |
| Rectal SCC | 163 | 5 (3.1) | 5.5 (2.3–13.5) | 4.1 (1.7–10.1) |
| Rectal non-SCC | 386 | 5 (1.3) | 2.7 (1.1 −6.4) | 2.0 (0.8–4.9) |
| Anus | 1744 | 32 (1.8) | 3.6 (2.5–5.1) | 2.6 (1.8–3.6) |
| Liver | 1377 | 13 (0.9) | 2.0 (1.2–3.5) | 1.7 (1.0–3.0) |
| Lung | 3111 | 24 (0.8) | 1.6 (1.1 −2.4) | 1.2 (0.8–1.8) |
| Kaposi sarcoma | 2379 | 44 (1.9) | 4.6 (3.4–6.2) | 2.0 (1.5–2.7) |
| Female breast | 873 | 5 (0.6) | 1.7 (0.7–4.1) | 1.4 (0.6–3.4) |
| Prostate | 1803 | 7 (0.4) | 0.7 (0.3–1.4) | 0.6 (0.3–1.3) |
| Kidney | 441 | 5 (1.1) | 2.4 (1.0–5.7) | 2.0 (0.8–4.9) |
| Myeloid malignanciesb | 447 | 19 (4.3) | 9.7 (6.1–15.4) | 7.1 (4.5–11.3) |
| Miscellaneousc | 1237 | 19 (1.5) | 3.4 (2.1 −5.3) | 2.5 (1.6–3.9) |
Highlighted aHRs and 95% CIs indicate estimates that were statistically significant with P less than 0.05. Estimates for risk of all evaluated nonlymphoid cancers including those with less than five previous lymphoid malignancies are provided in Supplemental Table 2. Model 2: models adjusted for sex/risk group, race/ethnicity, calendar year of cohort entry, and prior AIDS diagnosis and time since HIV diagnosis as time-varying covariates. Models 1 and 2 had age as the time scale. aHR, adjusted hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.
Model 1: models adjusted for sex/risk group, race/ethnicity, and calendar year of cohort entry.
Myeloid malignancies include myelodysplasia, myeloproliferative neoplasms, and other myeloid malignancies.
Miscellaneous cancers include cancers of the following sites: salivary glands (N = 32), other oral cavity/pharynx (N = 85), small intestine (N = 70), other gastrointestinal tract (N = 33), other respiratory tract (N = 49), bone and cartilage (N = 77), male breast (N = 32), other female genital tract (N = 88), other male genital tract (N = 25), eye and orbit (N = 39), other urinary tract (N = 21), other endocrine glands (N = 26), and unknown primary site (N = 660).